DLX6 and hepatocellular carcinoma: One study demonstrated that DLX6-AS1 is highly expressed in HCC and serves as an oncogene targeting the DLX6-AS1/miR-203a/matrix metallopeptidase 2 (MMP-2) pathway (Zhang et al., 2017).